Sleep & Recovery

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

The Most Common Community GHRH Analog — Sold Under Three Names. The DAC Confusion That Has Been Causing Purchasing Errors for a Decade. Why DAC Changes Everything About the Dosing Protocol. The Four Substitutions That Make Mod GRF 1-29 Last Long Enough to Work. How the GHRH Receptor and GHS-R1a Receptors Synergize. Why Teichman 2006 Actually Studied CJC-1295 WITH DAC — Not This Compound. The Empty Stomach Rule Is Not Optional.

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

Isolated 1977. Named for Sleep. 40+ Years of Research. No Gene Found. No Specific Receptor Identified. Half-Life 15 Minutes In Vitro — Yet Produces Multi-Night Effects. Studied for Sleep, Stress, Alcohol Withdrawal, Opiate Withdrawal, Neuroprotection, and Longevity. The Most Mechanistically Mysterious Compound in this reference.

40 Years of Research From One Lab. The Most Cited Telomere Peptide in the Longevity Space. The First Independent Replication Was Published in 2025.

The DAC distinction determines whether this is a physiologic pulse strategy or a prolonged GH-axis exposure strategy.

The Most Potent Injectable GHRP. Japan-Approved as a Diagnostic Agent. WADA S2 Banned. The Cortisol Problem That Cuts Against What You're Using It For. The Compound the Community Has Mostly Moved Past — and Why Understanding It Anyway Matters.

The Compound Every Secretagogue in this reference Targets. 191 Amino Acids. FDA-Approved for GH Deficiency, HIV Wasting, Short Bowel Syndrome. July 2025: Skytrofa Once-Weekly Now Approved for Adults. The Pulsatile vs Continuous GH Exposure Distinction. IGF-1 as the Surrogate Marker. The Fake HGH Crisis. WADA S2 Absolute Ban. Why Secretagogues (Sermorelin, Ipamorelin, MK-677) Are Different. The Active Malignancy Hard Stop. The Cancer-IGF-1 Question That Never Goes Away.

The Compound Defined by What It Doesn’t Do. Every GHRP Before It Elevated Cortisol and Prolactin. Ipamorelin Was Designed to Produce a Clean GH Pulse Without HPA Axis Activation. Raun et al. 1998: 'The First Selective Growth Hormone Secretagogue.' Why the Community Switched From GHRP-6 to Ipamorelin for Most Applications. The GH Stack Partner. The Empty Stomach Rule. Why Selectivity Matters in Practice.

The Soviet-Era Parkinson’s and Depression Compound Hiding in Limitless’s Catalog. A Tripeptide That Blocks Opioid Effects, Sensitizes D2 Dopamine Receptors, and Has a 5-Day Plasma Half-Life. The Research That Ceased When the Soviet Union Collapsed. What the 2010 Khan et al. Brain Activation Paper Actually Found. NOT the Same as MIF (Macrophage Migration Inhibitory Factor). Why “Melanocyte-Inhibiting Factor” Is a Historical Misnomer.

Oral non-peptide ghrelin receptor agonist that increases GH/IGF-1 signaling while carrying appetite, glucose, edema, and lethargy tradeoffs.

The Compound Synthesized in 2024 That Vendors Claim Is Superior to MK-677. 92% Higher Binding Affinity, 18-22 Hour IGF-1 Elevation, Fluorinated Backbone for Metabolic Stability — According to Vendor Specifications. What Independent Published Research Actually Exists: Essentially None. How to Use MK-677’s Clinical Evidence as the Pharmacological Framework While Being Honest That MK-777’s Specific Properties Are Unvalidated. WADA S2. Limitless Capsules.

Tuftsin → Selank → N-Acetyl Selank Amidate: Three Generations of Molecular Engineering. Russian-Approved Anxiolytic Without Sedation, Without Tolerance, Without Dependence. Comparable to Benzodiazepines for GAD With Psychostimulant Properties They Lack. BDNF Upregulation. Enkephalin Stabilization. The Evidence Is for Selank. NASA Is the More Stable Delivery Format Whose Equivalent Efficacy Is Chemically Logical but Clinically Unproven.

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

The Compound That Is 1,000x More Potent Than Piracetam by Weight. The Prodrug Whose Active Metabolite Is Endogenous to the Human Brain. Phase III Clinical Trials Exist — In Russian. Russian OTC Approval Since 2006 — Based on Real Trials That Western Evidence-Based Reviewers Cannot Read. Why It Is Not a Racetam Despite What Everyone Says. Cycloprolylglycine: The Metabolite That Does the Work. Enhanced Dreams as a Pharmacological Signal. The Dose Ceiling That Most Community Users Ignore.

The 7-Amino-Acid Antidepressant That Works in 4 Days Instead of 4 Weeks. TREK-1: The Potassium Channel That Keeps You Depressed. IC50 of 0.12 nM — 333x More Potent Than Its Parent Spadin. Duration Extended to 23 Hours vs 7 Hours. Hippocampal Neurogenesis in 4 Days. The Same One French Research Group Since 2010. Zero Human Trials. A Novel Mechanism That Bypasses the Serotonin Transporter Entirely.

Short Khavinson tripeptide positioned for brain and pineal-gland bioregulation. The appeal is cognitive aging, neuroprotection, and circadian support; the limitation is that the evidence is mostly single-institution preclinical work, not human clinical validation.

Russia Approved It. The West Has Never Independently Validated It. And It Might Be the Only Anxiolytic That Doesn't Make You Stupid.

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.